- In an SEC filing, Chimerix (NASDAQ:CMRX) notes that it terminated its license agreement with the Regents of the University of California.
- That license was formed in 2002 and covers the university's patent rights in inventions related to lipid-conjugated antiviral compounds and their use -- which include patents covering CMX001/brincidofovir, set to expire in 2020.
- The license's end doesn't affect Chimerix's solely owned patents covering CMX001/brincidofovir composition of matter, set to expire in 2034.